118 related articles for article (PubMed ID: 38929666)
1. Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients.
Medić-Milijić N; Jovanić I; Nedeljković M; Marković I; Spurnić I; Milovanović Z; Ademović N; Tomić T; Tanić N; Tanić N
Life (Basel); 2024 May; 14(6):. PubMed ID: 38929666
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).
Mishra A; Mishra SK; Sharanappa V; Krishnani N; Kumari N; Agarwal G
Indian J Surg Oncol; 2024 Jun; 15(2):250-257. PubMed ID: 38741650
[TBL] [Abstract][Full Text] [Related]
3. The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Meng Y; Wu H; Yao Y; Li R
Gland Surg; 2020 Dec; 9(6):2106-2115. PubMed ID: 33447561
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
Mirili C; Paydas S; Kilic EB; Seydaoglu G; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M; Ergin M; Zorludemir S
J BUON; 2020; 25(1):159-167. PubMed ID: 32277627
[TBL] [Abstract][Full Text] [Related]
7. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
[TBL] [Abstract][Full Text] [Related]
8. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
9. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
10. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
15. Expression and Clinical Significance of
Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
[TBL] [Abstract][Full Text] [Related]
16. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
17. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.
Mansouri H; Alcaraz LB; Mollevi C; Mallavialle A; Jacot W; Boissière-Michot F; Simony-Lafontaine J; Laurent-Matha V; Roger P; Liaudet-Coopman E; Guiu S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429078
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.
Li YZ; Chen B; Lin XY; Zhang GC; Lai JG; Li C; Lin JL; Guo LP; Xiao WK; Mok H; Ren CY; Wen LZ; Cao FR; Lin X; Qi XF; Liu Y; Liao N
Front Oncol; 2022; 12():830124. PubMed ID: 35402236
[TBL] [Abstract][Full Text] [Related]
20. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]